echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Eastern Sunshine Herbal Escitalopram Oxalate Tablets Entered the Administrative Approval Stage

    Eastern Sunshine Herbal Escitalopram Oxalate Tablets Entered the Administrative Approval Stage

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Dongyang Sun Pharmaceutical has entered the administrative approval stage with the imitation of escitalopram oxalate tablets reported for production in category 4, and is expected to become the company's second antidepressant approved for marketing.


    Escitalopram is the single-S-enantiomer of citalopram, a bicyclic hydrogenated phthalide derivative, and is clinically used to treat depression, panic disorder with or without agoraphobia.


    According to data from Meinenet, the total sales of escitalopram oxalate tablets in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2019 exceeded 20 100 million yuan, the growth rate has declined in the first half of 2020.


    Consistency evaluation and application status of escitalopram oxalate tablets (including new classification for production)

    Source: Meinenet MED2.


    At present, 5 companies have submitted supplementary applications for the consistency evaluation of escitalopram oxalate tablets.


    From 2021 to the present, Dongyang Pharmaceutical has been approved for marketing

    Source: Meinenet MED2.


    According to data from Minai.


    New antidepressant drug being developed by Dongyang Sun Pharmaceutical

    Source: Meinenet MED2.


    In terms of new antidepressant drugs, the domestic class 1 new drug HEC113995PA·H2O tablets are in phase I clinical trials, and the 2.


    Source: Minet database

    Note: The statistics are as of March 25.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.